In Europe roughly one child in 4,000 is born with a hereditary retina disorder. The most common disorder is retinitis pigmentosa, of which there are a number of different variants. Although ophthalmologists can diagnose the destruction of nerve cells in the retina, in most cases they can’t offer patients any treatment. In addition, the way the disorder develops varies from patient to patient. Some patients go completely blind, in others their vision is “only” seriously impaired. “This uncertainty is there in the back of the minds of those affected, ” says Franz Badura, a member of the board of the Pro Retina Foundation and head of the Department of Research and Therapy of the self-help organization Pro Retina Deutschland e.V.
So far researchers have succeeded in characterizing almost 140 genes and in finding the genes that cause the hereditary eye disorder. “There are about 40 different genes involved in the various forms of retinitis pigmentosa alone,“ says Professor Bernhard Weber, director of the Institute for Human Genetics at the University of Regensburg. This enormous genetic variety is one reason why until now human geneticists have only been able to find the responsible gene in 10-20 percent of patients. In this situation it is, for example, difficult or even impossible to predict how great a child’s risk is of developing the disease.
This will now be changed by the Ret Chip. The chip contains 300,000 base pairs – the building blocks of the genetic substance DNA – and 72 different genes, which can be analyzed in parallel in a single process. As well as the genes that cause the different forms of retinitis pigmentosa and the hereditary forms of macula degeneration, the chip also includes a group of genes which not only cause the retina to degenerate but are also responsible for problems in other organs, such as Usher syndrome and Bardet-Biedl syndrome.“The new technology will now allow us to test a very large number of genes simultaneously, thus increasing the likelihood of detecting a mutation and thus the cause of the disease. That is of course a huge step forward,” Weber says.
More precise diagnosis may make it easier in the future for doctors to make a prognosis, i. e., to predict how the disease will develop in individual cases and thus allay the fears and uncertainty of many patients. “In Morbus Stargardt, for example, the mutation allows us to see whether the corresponding protein is actually being produced or to what extent it is still active. We can thus say approximately how the disease will develop,” Weber explains.
Initially the Regensburg researchers will be subjecting the chip to critical tests in collaboration with several centres in Germany. At the centres in Berlin, Bonn-Siegburg, Tübingen and Regensburg patients will undergo clinical examinations and will receive a genetic consultation. There a blood sample will be taken that will then be genetically analyzed back in Regensburg. “In view of the new approaches in the field of gene therapy the status of molecular diagnostics is growing,” Franz Badura stresses. “It will become increasingly important for patients to know the genetic causes of their disorders.”
The Pro Retina Foundation for the Prevention of Blindness, supported by the self-help organization for people with degeneration of the retina, Pro Retina e.V., provided 250,000 euros in funding for the development of the Ret Chip. “Our organization has been involved in research funding for many years and has so far raised one million euros,” says Dr. Claus Gehrig, chairman of the patients’ organization. “The Ret-Chip will clearly have a direct link to patients,” Gehrig continued. “That is more than just basic research. We hope very much that the new technology will make the diagnosis and prognosis of hereditary retina disorders easier.”
It is not yet clear exactly how expensive a Ret-Chip examination will be, since not all the genes on the chip need to be used fully in every case, but Weber thinks it will cost between 3,000 and 4,000 euros. It is expected that the cost will be borne by the health insurance funds.
Barbara Ritzert | alfa
New discoveries predict ability to forecast dementia from single molecule
12.12.2018 | UT Southwestern Medical Center
Pain: Perception and motor impulses arise in the brain independently of one another
12.12.2018 | Technische Universität München
What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.
The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...
A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.
Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...
Over the last decade, there has been much excitement about the discovery, recognised by the Nobel Prize in Physics only two years ago, that there are two types...
What if a sensor sensing a thing could be part of the thing itself? Rice University engineers believe they have a two-dimensional solution to do just that.
Rice engineers led by materials scientists Pulickel Ajayan and Jun Lou have developed a method to make atom-flat sensors that seamlessly integrate with devices...
12.12.2018 | Event News
10.12.2018 | Event News
06.12.2018 | Event News
13.12.2018 | Life Sciences
13.12.2018 | Physics and Astronomy
13.12.2018 | Earth Sciences